Pharmacologic Approaches to Electrolyte Abnormalities in Heart Failure

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Electrolyte abnormalities are common in heart failure and can arise from a variety of etiologies. Neurohormonal activation from ventricular dysfunction, renal dysfunction, and heart failure medications can perturb electrolyte homeostasis which impact both heart failure-related morbidity and mortality. These include disturbances in serum sodium, chloride, acid-base, and potassium homeostasis. Pharmacological treatments differ for each electrolyte abnormality and vary from older, established treatments like the vaptans or acetazolamide, to experimental or theoretical treatments like hypertonic saline or urea, or to newer, novel agents like the potassium binders: patiromer and zirconium cyclosilicate. Pharmacologic approaches range from limiting electrolyte intake or directly repleting the electrolyte, to blocking or promoting their resorption, and to neurohormonal antagonism. Because of the prevalence and clinical impact of electrolyte abnormalities, understanding both the older and newer therapeutic options is and will continue to be necessity for the management of heart failure.

Original languageEnglish (US)
Pages (from-to)181-189
Number of pages9
JournalCurrent Heart Failure Reports
Volume13
Issue number4
DOIs
StatePublished - Aug 1 2016

Fingerprint

Electrolytes
Heart Failure
Potassium
Homeostasis
Ventricular Dysfunction
Acetazolamide
Sodium Chloride
Renal Insufficiency
Urea
Pharmacology
Morbidity
Acids
Mortality
Serum

Keywords

  • Electrolytes
  • Heart failure
  • Hyperkalemia
  • Hypochloremia
  • Hyponatremia
  • Metabolic alkalosis
  • Treatment

ASJC Scopus subject areas

  • Emergency Medicine
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Pharmacologic Approaches to Electrolyte Abnormalities in Heart Failure. / Grodin, Justin L.

In: Current Heart Failure Reports, Vol. 13, No. 4, 01.08.2016, p. 181-189.

Research output: Contribution to journalReview article

@article{614b384902ac4cf2882de34df6c91487,
title = "Pharmacologic Approaches to Electrolyte Abnormalities in Heart Failure",
abstract = "Electrolyte abnormalities are common in heart failure and can arise from a variety of etiologies. Neurohormonal activation from ventricular dysfunction, renal dysfunction, and heart failure medications can perturb electrolyte homeostasis which impact both heart failure-related morbidity and mortality. These include disturbances in serum sodium, chloride, acid-base, and potassium homeostasis. Pharmacological treatments differ for each electrolyte abnormality and vary from older, established treatments like the vaptans or acetazolamide, to experimental or theoretical treatments like hypertonic saline or urea, or to newer, novel agents like the potassium binders: patiromer and zirconium cyclosilicate. Pharmacologic approaches range from limiting electrolyte intake or directly repleting the electrolyte, to blocking or promoting their resorption, and to neurohormonal antagonism. Because of the prevalence and clinical impact of electrolyte abnormalities, understanding both the older and newer therapeutic options is and will continue to be necessity for the management of heart failure.",
keywords = "Electrolytes, Heart failure, Hyperkalemia, Hypochloremia, Hyponatremia, Metabolic alkalosis, Treatment",
author = "Grodin, {Justin L.}",
year = "2016",
month = "8",
day = "1",
doi = "10.1007/s11897-016-0295-7",
language = "English (US)",
volume = "13",
pages = "181--189",
journal = "Current Alzheimer Research",
issn = "1531-0035",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Pharmacologic Approaches to Electrolyte Abnormalities in Heart Failure

AU - Grodin, Justin L.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Electrolyte abnormalities are common in heart failure and can arise from a variety of etiologies. Neurohormonal activation from ventricular dysfunction, renal dysfunction, and heart failure medications can perturb electrolyte homeostasis which impact both heart failure-related morbidity and mortality. These include disturbances in serum sodium, chloride, acid-base, and potassium homeostasis. Pharmacological treatments differ for each electrolyte abnormality and vary from older, established treatments like the vaptans or acetazolamide, to experimental or theoretical treatments like hypertonic saline or urea, or to newer, novel agents like the potassium binders: patiromer and zirconium cyclosilicate. Pharmacologic approaches range from limiting electrolyte intake or directly repleting the electrolyte, to blocking or promoting their resorption, and to neurohormonal antagonism. Because of the prevalence and clinical impact of electrolyte abnormalities, understanding both the older and newer therapeutic options is and will continue to be necessity for the management of heart failure.

AB - Electrolyte abnormalities are common in heart failure and can arise from a variety of etiologies. Neurohormonal activation from ventricular dysfunction, renal dysfunction, and heart failure medications can perturb electrolyte homeostasis which impact both heart failure-related morbidity and mortality. These include disturbances in serum sodium, chloride, acid-base, and potassium homeostasis. Pharmacological treatments differ for each electrolyte abnormality and vary from older, established treatments like the vaptans or acetazolamide, to experimental or theoretical treatments like hypertonic saline or urea, or to newer, novel agents like the potassium binders: patiromer and zirconium cyclosilicate. Pharmacologic approaches range from limiting electrolyte intake or directly repleting the electrolyte, to blocking or promoting their resorption, and to neurohormonal antagonism. Because of the prevalence and clinical impact of electrolyte abnormalities, understanding both the older and newer therapeutic options is and will continue to be necessity for the management of heart failure.

KW - Electrolytes

KW - Heart failure

KW - Hyperkalemia

KW - Hypochloremia

KW - Hyponatremia

KW - Metabolic alkalosis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84973594787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973594787&partnerID=8YFLogxK

U2 - 10.1007/s11897-016-0295-7

DO - 10.1007/s11897-016-0295-7

M3 - Review article

C2 - 27278221

AN - SCOPUS:84973594787

VL - 13

SP - 181

EP - 189

JO - Current Alzheimer Research

JF - Current Alzheimer Research

SN - 1531-0035

IS - 4

ER -